Virotherapy Against Malignant Glioma Stem Cells

Overview

Journal Cancer Lett

Specialty Oncology

Date 2009 Aug 1

PMID 19643532

Citations 17

Authors

Mahua Dey

Ilya V Ulasov

Maciej S Lesniak

Affiliations

Soon will be listed here.

Abstract

Glioblastoma multiforme, the most common primary intracranial malignancy, is associated with very poor outcome despite advances in surgical techniques and chemo- and radiation therapy. Many novel treatment modalities are being investigated with varying amount of success. Evolution of cancer stem cell hypothesis provides a new venue for developmental therapeutics. In this review, we highlight the literature regarding the existence of glioma stem cells and their characteristics. We also discuss the potential for virotherapy, a novel therapeutic approach utilizing conditionally replicative viruses, to directly target this population of self-renewing cancer stem cells.

Citing Articles

The Role of Mesenchymal Reprogramming in Malignant Clonal Evolution and Intra-Tumoral Heterogeneity in Glioblastoma.

Wu Q, Berglund A, Macaulay R, Etame A Cells. 2024; 13(11.

PMID: 38891074 PMC: 11171993. DOI: 10.3390/cells13110942.

Eltanexor Effectively Reduces Viability of Glioblastoma and Glioblastoma Stem-Like Cells at Nano-Molar Concentrations and Sensitizes to Radiotherapy and Temozolomide.

Otte K, Zhao K, Braun M, Neubauer A, Raifer H, Helmprobst F Biomedicines. 2022; 10(9).

PMID: 36140245 PMC: 9496210. DOI: 10.3390/biomedicines10092145.

Inhibition of Carbonic Anhydrase 2 Overcomes Temozolomide Resistance in Glioblastoma Cells.

Zhao K, Schafer A, Zhang Z, Elsasser K, Culmsee C, Zhong L Int J Mol Sci. 2022; 23(1).

PMID: 35008590 PMC: 8745118. DOI: 10.3390/ijms23010157.

LncRNA MIR155HG Promotes Temozolomide Resistance by Activating the Wnt/β-Catenin Pathway Via Binding to PTBP1 in Glioma.

He X, Sheng J, Yu W, Wang K, Zhu S, Liu Q Cell Mol Neurobiol. 2020; 41(6):1271-1284.

PMID: 32529543 PMC: 11448642. DOI: 10.1007/s10571-020-00898-z.

Comparative Transcriptomic Analysis of Temozolomide Resistant Primary GBM Stem-Like Cells and Recurrent GBM Identifies Up-Regulation of the Carbonic Anhydrase Gene as Resistance Factor.

Hannen R, Selmansberger M, Hauswald M, Pagenstecher A, Nist A, Stiewe T Cancers (Basel). 2019; 11(7).

PMID: 31262047 PMC: 6678269. DOI: 10.3390/cancers11070921.

References

Lamfers M, Grill J, Dirven C, van Beusechem V, Geoerger B, van den Berg J . Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res. 2002; 62(20):5736-42. View

van Houdt W, Haviv Y, Lu B, Wang M, Rivera A, Ulasov I . The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma. J Neurosurg. 2006; 104(4):583-92. DOI: 10.3171/jns.2006.104.4.583. View

Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir I . Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer. 2006; 5:67. PMC: 1697823. DOI: 10.1186/1476-4598-5-67. View

Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A . Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-60. DOI: 10.1038/nature05236. View

Wong A, Bigner S, Bigner D, Kinzler K, Hamilton S, Vogelstein B . Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci U S A. 1987; 84(19):6899-903. PMC: 299192. DOI: 10.1073/pnas.84.19.6899. View

Chiocca E, Abbed K, Tatter S, Louis D, Hochberg F, Barker F . A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther. 2004; 10(5):958-66. DOI: 10.1016/j.ymthe.2004.07.021. View

Freeman A, Zakay-Rones Z, Gomori J, Linetsky E, Rasooly L, Greenbaum E . Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther. 2005; 13(1):221-8. DOI: 10.1016/j.ymthe.2005.08.016. View

Grill J, van Beusechem V, van der Valk P, Dirven C, Leonhart A, Pherai D . Combined targeting of adenoviruses to integrins and epidermal growth factor receptors increases gene transfer into primary glioma cells and spheroids. Clin Cancer Res. 2001; 7(3):641-50. View

Libermann T, Nusbaum H, Razon N, Kris R, Lax I, Soreq H . Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature. 1985; 313(5998):144-7. DOI: 10.1038/313144a0. View

10.

Markert J, Medlock M, Rabkin S, Gillespie G, Todo T, Hunter W . Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 2000; 7(10):867-74. DOI: 10.1038/sj.gt.3301205. View

11.

Hamburger A, Salmon S . Primary bioassay of human tumor stem cells. Science. 1977; 197(4302):461-3. DOI: 10.1126/science.560061. View

12.

Ulasov I, Zhu Z, Tyler M, Han Y, Rivera A, Khramtsov A . Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. Hum Gene Ther. 2007; 18(7):589-602. DOI: 10.1089/hum.2007.002. View

13.

Shmelkov S, Jun L, St Clair R, McGarrigle D, Derderian C, Usenko J . Alternative promoters regulate transcription of the gene that encodes stem cell surface protein AC133. Blood. 2003; 103(6):2055-61. DOI: 10.1182/blood-2003-06-1881. View

14.

Cassel W, GARRETT R . NEWCASTLE DISEASE VIRUS AS AN ANTINEOPLASTIC AGENT. Cancer. 1965; 18:863-8. DOI: 10.1002/1097-0142(196507)18:7<863::aid-cncr2820180714>3.0.co;2-v. View

15.

Uchida N, Buck D, He D, Reitsma M, Masek M, Phan T . Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci U S A. 2000; 97(26):14720-5. PMC: 18985. DOI: 10.1073/pnas.97.26.14720. View

16.

Eramo A, Ricci-Vitiani L, Zeuner A, Pallini R, Lotti F, Sette G . Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ. 2006; 13(7):1238-41. DOI: 10.1038/sj.cdd.4401872. View

17.

Khuri F, Nemunaitis J, Ganly I, Arseneau J, Tannock I, Romel L . a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med. 2000; 6(8):879-85. DOI: 10.1038/78638. View

18.

Yang L, Cao Z, Li F, Post D, Van Meir E, Zhong H . Tumor-specific gene expression using the survivin promoter is further increased by hypoxia. Gene Ther. 2004; 11(15):1215-23. PMC: 3163156. DOI: 10.1038/sj.gt.3302280. View

19.

Parr M, Manome Y, Tanaka T, Wen P, Kufe D, Kaelin Jr W . Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nat Med. 1997; 3(10):1145-9. DOI: 10.1038/nm1097-1145. View

20.

Markovitz N, Baunoch D, Roizman B . The range and distribution of murine central nervous system cells infected with the gamma(1)34.5- mutant of herpes simplex virus 1. J Virol. 1997; 71(7):5560-9. PMC: 191798. DOI: 10.1128/JVI.71.7.5560-5569.1997. View